Peptides / Immune and antimicrobial

Synthetic analog · 14 amino acids · 1,553.8 Da

Murepavadin

Murepavadin is an experimental peptide-like antibiotic against Pseudomonas aeruginosa, not approved, and its IV phase 3 trials stopped after a kidney injury signal. Studies in people tested how the body handles it and tracked side effects, and lab studies tested it against bacteria. PepBank shows 11 results on murepavadin from 2 studies in people, and 51 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as POL-7080, POL7080, RG-7929, RG7929, RO-7033877, RO7033877

Evidence level: Mostly animal studies51 of 62 results come from studies in animals and lab cells. 2 studies in people.

Results in people

18% of 62 results

Results in animals

10% of 62 results

Results in lab cells

73% of 62 results

From computer models

0% of 62 results

Overview

Murepavadin at a glance

What it is	Synthetic analog, 14 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	21 studies with results. 18 of them gave murepavadin, with 62 results. 11 in people6 in animals45 in lab cells
Best study in people	Randomized controlled trial (2018)
Clinical trials	9 registered: 0 active or planned, 0 with posted results

The science

What is murepavadin?

A cyclic peptidomimetic antibiotic studied against Pseudomonas aeruginosa.

Amino acids in one chain

The history of murepavadin

2013April
A registered trial of murepavadin started (NCT02110459).
2017
The oldest paper on murepavadin in PepBank is from 2017.

Murepavadin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Murepavadin is a synthetic analog of 14 amino acids, with a ring, 9 changed amino acids.

Formula

C₇₃H₁₁₂N₂₂O₁₆

Molecular weight

1,553.8 g/mol

CAS number

944252-63-5

Target

Lipopolysaccharide transport protein D (LptD) (gene lptD): inhibitorEvidence: Primary human pharmacokinetic study describes LptD binding and inhibition of lipopolysaccharide transport.

Development

Polyphor / Spexis (historical), Cyaris (current sponsor website). Highest phase: phase 3.

Identifiers

PubChem 91824766, ChEMBL CHEMBL3946483, UNII 0D02GRY87Z, DrugBank DB14777, KEGG D10957, IUPHAR 10832

SMILES and InChIKey

Three-letter sequence
cyclo(L-Ala-L-Ser-D-Pro-L-Pro-L-Thr-L-Trp-L-Ile-L-Dab-L-Orn-D-Dab-L-Dab-L-Trp-L-Dab-L-Dab)

InChIKey
RIDRXGOBXZLKHZ-NZUANIILSA-N

SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN

See charge, composition and 3D structure on the Scientific page

The evidence

What murepavadin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies51 of 62 results come from studies in animals and lab cells. 2 studies in people.

Infections

32 results · 32 lab

In lab tests, murepavadin MIC50 and MIC90 were both 0.12 mg/liter. Antimicrobial agents and chemotherapy, 2018

Immune system and inflammation

1 result · 1 lab

In lab tests, murepavadin did not neutralize LPS in a macrophage assay. ACS infectious diseases, 2023

All 2 studies in people

In people

In healthy men, murepavadin half-life ranged from 2.52 to 5.30 h after a single dose.

2018Antimicrobial agents and chemotherapy

In people

In people with renal impairment, murepavadin plasma AUC was about 2.0- to 2.5-fold higher than with normal renal function.

2018Antimicrobial agents and chemotherapy32 people

All 21 murepavadin studies by area Open the Scientific page

Key murepavadin studies

Studies in people come first, then studies in animals and in the lab.

People
Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses
Wach et al. 2018 · Antimicrobial agents and chemotherapy · cited by 34
6 results
People
Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment
Dale et al. 2018 · Antimicrobial agents and chemotherapy · 32 people · cited by 29
5 results
Animals
Murepavadin, a Small Molecule Host Defense Peptide Mimetic, Activates Mast Cells <i>via</i> MRGPRX2 and MrgprB2
Amponnawarat et al. 2021 · Frontiers in immunology · cited by 24
8 results
Animals
Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models
Melchers et al. 2019 · Antimicrobial agents and chemotherapy · cited by 24
5 results
Lab cells
Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China
Sader et al. 2018 · Antimicrobial agents and chemotherapy · 1,219 subjects · cited by 46
5 results

All 21 Murepavadin studies

Murepavadin clinical trials

ClinicalTrials.gov lists 9 trials of murepavadin. 0 are active or planned, and 0 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Phase 3terminated41 planned

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

Phase 3terminated2 planned

Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia

Phase 2completed25 people

1 Murepavadin trial

Status and safety

Is murepavadin approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Murepavadin side effects and safety

PepBank has 3 safety results from studies of murepavadin. 3 of them come from studies in people.

Safety results from studies (3)

In healthy men, murepavadin adverse events were temporary and generally mild. (Antimicrobial agents and chemotherapy, 2018)
In people across all renal function groups, murepavadin was well tolerated. (Antimicrobial agents and chemotherapy, 2018)
In healthy men, researchers identified no dose-limiting toxicity with murepavadin. (Antimicrobial agents and chemotherapy, 2018)

See every safety result on the Scientific page

Doses studied (2 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
2.2 mg/kg	Human	human	intravenous infusion	single dose over 3 h	Trial in people without random groups · n = 32	Dale 2018
32 mg/L	Lab	Pseudomonas aeruginosa	Not reported	1-5 h	Study on cells in a dish	Díez-Aguilar 2021

Questions and more

Ask a question about murepavadin

The answer links to every study it uses.

What does the evidence say about murepavadin?Is murepavadin tested in people?Compare with Thymosin alpha-1 Compare with LTX-315

Sources

Database: PepBank data for murepavadin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about murepavadin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Murepavadin

Murepavadin at a glance